About: Early predictors of non-response to interferon in multiple sclerosis     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
rdfs:seeAlso
Description
  • Objective - To identify early clinical and MRI predictors of non-response to interferon (IFN) treatment in multiple sclerosis (MS). Methods - In 172 patients with relapsing-remitting MS treated with IFN beta, we evaluated prediction of future treatment non-response. Candidate predictors comprised disability and its sustained progression, relapse score (combining frequency and severity of relapses), brain volume change, brain parenchymal fraction, number of new T2 lesions, and T2 and T1 lesion volume within the initial year of treatment. Treatment non-response was evaluated as confirmed disability progression or overall average annual relapse score exceeding 1 over the following 5 years. Logistic regression model was adjusted for patient age, gender, disease duration and changes in treatment. Results - Ninety patients (52%) reached the status of IFN non-responders in years 2-6. Patients with >= 1 new T2 lesion and relapse score >= 2 (odds ratio >= 5.7) or those with >= 3 new T2 lesions regardless of the relapse score (odds ratio = 3) were in a significantly higher risk of future treatment non-response. Conclusions - In patients with MS treated with IFN beta for 1 year, number of new T2 lesions and annualized relapse score predict individual risk of treatment non-response over the following 5 years.
  • Objective - To identify early clinical and MRI predictors of non-response to interferon (IFN) treatment in multiple sclerosis (MS). Methods - In 172 patients with relapsing-remitting MS treated with IFN beta, we evaluated prediction of future treatment non-response. Candidate predictors comprised disability and its sustained progression, relapse score (combining frequency and severity of relapses), brain volume change, brain parenchymal fraction, number of new T2 lesions, and T2 and T1 lesion volume within the initial year of treatment. Treatment non-response was evaluated as confirmed disability progression or overall average annual relapse score exceeding 1 over the following 5 years. Logistic regression model was adjusted for patient age, gender, disease duration and changes in treatment. Results - Ninety patients (52%) reached the status of IFN non-responders in years 2-6. Patients with >= 1 new T2 lesion and relapse score >= 2 (odds ratio >= 5.7) or those with >= 3 new T2 lesions regardless of the relapse score (odds ratio = 3) were in a significantly higher risk of future treatment non-response. Conclusions - In patients with MS treated with IFN beta for 1 year, number of new T2 lesions and annualized relapse score predict individual risk of treatment non-response over the following 5 years. (en)
Title
  • Early predictors of non-response to interferon in multiple sclerosis
  • Early predictors of non-response to interferon in multiple sclerosis (en)
skos:prefLabel
  • Early predictors of non-response to interferon in multiple sclerosis
  • Early predictors of non-response to interferon in multiple sclerosis (en)
skos:notation
  • RIV/00064165:_____/12:11531!RIV13-MZ0-00064165
http://linked.open...avai/predkladatel
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • I, Z(MSM0021620849)
http://linked.open...iv/cisloPeriodika
  • 6
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 132642
http://linked.open...ai/riv/idVysledku
  • RIV/00064165:_____/12:11531
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • Brain atrophy; interferon; MRI; prediction; relapse score; volumetry; double-blind; beta; therapy; disease; trials; time; mri; ms; multicenter; disability (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • DK - Dánské království
http://linked.open...ontrolniKodProRIV
  • [CB16CBFB2E8B]
http://linked.open...i/riv/nazevZdroje
  • Acta Neurologica Scandinavica
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 126
http://linked.open...iv/tvurceVysledku
  • Havrdová, Eva
  • Seidl, Zdeněk
  • Vaněčková, Manuela
  • Horáková, Dana
  • Krásenský, Jan
  • Doležal, Ondřej
  • Kalinčík, Tomáš
http://linked.open...ain/vavai/riv/wos
  • 000310545400005
http://linked.open...n/vavai/riv/zamer
issn
  • 0001-6314
number of pages
is http://linked.open...avai/riv/vysledek of
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software